Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01984346 · ClinicalTrials.gov registry record · NA
CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)
A NA study, sponsored by AtriCure.
- Completed
- Registry status
- NA
- Development phase
- 170
- Enrollment target
NCT01984346 is a NA study that has completed, run by AtriCure. The registered enrollment target is 170 participants.
The verdict
NCT01984346, a NA study, has completed, sponsored by AtriCure.
- COMPLETED
- Registry status
- NA
- Development phase
- 170 participants
- Enrollment target
Study Summary
This is a multi-center, open label, randomized pivotal study evaluating the safety and efficacy of the EPi-Sense-AF Guided Coagulation System for the treatment of persistent AF patients, refractory or intolerant to at least one Class I and/or III Anti Arrhythmic Drug (AAD).
Interventions
- DEVICE AtriCure EPi-Sense-AF Guided Coagulation System with VisiTrax
- DEVICE Endocardial RF Catheter ablation using Open Irrigated-tip RF Abaltion Catheter with unidirectional or bidirectional steering
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2013-12 |
| Est. Completion | 2023-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01984346
The ClinicalTrials.gov registry entry for NCT01984346 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AtriCure, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AtriCure EPi-Sense-AF Guided Coagulation System with VisiTrax is the first listed.
NCT01984346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01984346 about?
NCT01984346 is a clinical study titled "CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)". This is a multi-center, open label, randomized pivotal study evaluating the safety and efficacy of the EPi-Sense-AF Guided Coagulation System for the treatment of persistent AF patients, refractory or intolerant to at least one Class I and/or III Anti Arrhythmic Drug (AAD).
What is the current status of trial NCT01984346?
This trial is currently completed. It is a NA study. The enrollment target is 170 participants. The study started on 2013-12. Estimated completion is 2023-10.
What interventions are being tested in trial NCT01984346?
The interventions under investigation include: AtriCure EPi-Sense-AF Guided Coagulation System with VisiTrax (DEVICE), Endocardial RF Catheter ablation using Open Irrigated-tip RF Abaltion Catheter with unidirectional or bidirectional steering (DEVICE).
Who is sponsoring clinical trial NCT01984346?
This trial is sponsored by AtriCure, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.